- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, August 2, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Becker’s Hospital Review and Security Magazine cited a study published in The American Journal of Managed Care® (AJMC®) that explored data breaches in hospitals. The study, “Data Breach Locations, Types, and Associated Characteristics Among US Hospitals,” found that paper and films were the most frequent location of breached data, occurring in 65 hospitals during the study period, whereas network servers were the least common location, but their breaches affected the most patients overall.
An article from the Pittsburgh Post-Gazette referenced an AJMC® supplement regarding the opioid epidemic. The supplement, “Deaths, Dollars, and Diverted Resources: Examining the Heavy Price of the Opioid Epidemic,” includes 9 articles exploring the economic burden of the opioid epidemic on the states, and more. The supplement was also picked up by The Heartland Institute.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed included an AJMC® interview with R. Brett McQueen, PhD, assistant professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado. During the interview, McQueen discussed the need to account for a myriad of criteria when determining cost effectiveness.
Thursday’s CER Daily Newsfeed included AJMC®’s interview with Jeroen Jansen, PhD, lead scientific advisor, Open-Source Value Project, Innovation and Value Initiative, in which he discussed challenges with today’s approaches to value assessment. The newsfeed also included the article “Ibrutinib—Rituximab Improves Survival Compared With Current Treatment for Chronic Lymphocytic Leukemia,” which reported on study findings showing the combination of ibrutinib and rituximab keeps patients with a common form of leukemia alive and disease free longer than the current treatment regimen.
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More
